UBS analyst John Sourbeer initiated coverage of Pacific Biosciences with a Neutral rating and $13 price target. The firm’s proprietary analysis and expert calls drive its projected 42% revenue CAGR ~in-line with consensus, and says that Pacific is launching into an increasingly competitive NGS market with lingering macro pressures, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PACB:
- Pacific Biosciences 17.5M share Spot Secondary priced at $10.00
- Pacific Biosciences $150M Spot Secondary; price range $10.00-$10.25
- Pacific Biosciences announces $150M common stock offering
- Pacific Biosciences downgraded to Neutral at Cantor Fitzgerald on valuation
- Pacific Biosciences downgraded to Neutral from Overweight at Cantor Fitzgerald